What is IntraVu?
IntraVu Inc. operates at the intersection of advanced engineering and clinical utility, specializing in the development of high-definition, minimally invasive arthroscopic systems. Its flagship product, the 30 SideVu, is recognized as the smallest needle scope arthroscopy device currently available, designed to facilitate precise diagnostic and surgical procedures with minimal tissue disruption. By prioritizing ergonomic, single-handed operation, IntraVu addresses critical pain points in surgical efficiency, allowing healthcare providers to perform complex procedures in both hospital and office-based settings. This focus on reducing patient recovery times while enhancing physician control positions the company as a disruptive force in the orthopedic and surgical device sectors.
How much funding has IntraVu raised?
IntraVu has raised a total of $378K across 2 funding rounds:
Debt
$150K
Debt
$228K
Debt (2020): $150K with participation from PPP
Debt (2021): $228K led by PPP
Key Investors in IntraVu
PPP
Public-Private Partnership
What's next for IntraVu?
With the recent influx of capital, IntraVu is expected to scale its commercial operations and expand its footprint in the global surgical center market. The strategic focus will likely shift toward increasing manufacturing capacity to meet rising demand for its needle-scope technology and potentially funding further research into next-generation imaging capabilities. As the company transitions through this late-stage growth phase, the emphasis will remain on clinical validation and the widespread adoption of its minimally invasive systems, ensuring that the firm maintains its competitive edge against traditional, larger-scale arthroscopic equipment providers.
See full IntraVu company page
